Search clinical trials for: MK3475-B84

Total 66 results

Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Novartis Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

Carcinoma, Renal Cell

United States, United Kingdom
Abbott Medical Devices

Completed

Avoid FFS - Use of the Atrial Pacemaker Lead 1699 With Very Short Tip Ring Spacing to Avoid Far Field Sensing (Avoid FFS)

Atrial Fibrillation | Bradycardia

Germany
University Medical Center Groningen

Completed

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Melanoma

Netherlands
Teclison Ltd.
Merck Sharp & Dohme LLC

Recruiting

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Colorectal Cancer; Lung Cancer

Taiwan, United States
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Samsung Medical Center

Completed

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

Hepatocellular Carcinoma

Korea, Republic of
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Advanced and Metastatic Urothelial Cancer

Spain, United States, France
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
Samsung Medical Center

Completed

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Biliary Tract Cancer

Korea, Republic of
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, Belgium, Denmark, France
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Stage IV Non-Small Cell Lung Cancer

Spain, United States, France, Japan
Seoul National University Hospital

Completed

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer (MISP-MK3475)

Small Cell Lung Cancer

Korea, Republic of
Centre Leon Berard

Active, not recruiting

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP)

Localized Resectable Tumor | MSI/dMMR or EBV-positive Gastric Cancers

France
Institut Bergonié
Merck Sharp & Dohme LLC; Ministry of Health, France; Immune Design

Active, not recruiting

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)

Sarcoma

France
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
MedSIR

Completed

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY)

Breast Cancer

Spain
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (PEMBRO-RT)

Non-Small Cell Lung Cancer

Netherlands
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
Samsung Medical Center

Active, not recruiting

Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Gastric Cancer

Korea, Republic of
Oslo University Hospital
Merck Sharp & Dohme LLC; Italian Sarcoma Group

Terminated

A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery (PROMO)

Osteosarcoma

Norway, Italy
McGill University Health Centre/Research Institute...

Recruiting

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell

Canada
Amsterdam UMC, location VUmc

Unknown

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

NSCLC, Stage I
National Cancer Center Hospital East
Merck Sharp & Dohme LLC; Eisai Co., Ltd.

Completed

Lenvatinib and Pembrolizumab Simultaneous Combination Study (Lenva+Pembro)

Advanced Gastric Cancer

Japan
NYU Langone Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Muscle-invasive Urothelial Cancer of the Bladder

United States
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan
Wilson Miller

Active, not recruiting

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Metastatic Malignant Melanoma

Canada
PDS Biotechnology Corp.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Neoplasms, Head and Neck

United States, Puerto Rico, Ireland, United Kingdom
NYU Langone Health
Merck Sharp & Dohme LLC

Terminated

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Relapsed Non-Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States
Sellas Life Sciences Group
Merck Sharp & Dohme LLC; Cancer Insight, LLC

Active, not recruiting

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Colorectal Cancer | Ovarian Cancer | Acute Myelogenous Leukemia | Small-cell Lung Cancer | Triple-negative Breast Cancer

United States
Teon Therapeutics, Inc.
Merck Sharp & Dohme LLC

Terminated

TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Cancer | Advanced Solid Tumor | Advanced Cancer | Oncology

United States
OncoC4, Inc.
Merck Sharp & Dohme LLC; GOG Foundation

Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
Curegenix Inc.
Merck Sharp & Dohme LLC

Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Solid Tumors | GI Cancer

United States, Taiwan
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Arrys Therapeutics
Merck Sharp & Dohme LLC

Completed

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Microsatellite Stable Colorectal Cancer

United States
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
Monica Mita
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Breast Cancer

United States
ENB Therapeutics, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Melanoma | Cancer | Pancreatic Cancer | Solid Tumor | Ovary Cancer

United States, Australia
Shenzhen Ionova Life Sciences Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Cancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, Solid

United States
L. Nicolas Gonzalez Castro, MD, PhD
Merck Sharp & Dohme LLC

Recruiting

Surgical Pembro +/- Olaparib w TMZ for rGBM

Glioblastoma | Recurrent Glioblastoma

United States
University of Colorado, Denver
Merck Sharp & Dohme LLC

Recruiting

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Gastric Cancer | GastroEsophageal Cancer

United States
MedPacto, Inc.

Recruiting

Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Medivir
Merck Sharp & Dohme LLC

Terminated

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Solid Tumors

United States
University of Oklahoma
Merck Sharp & Dohme LLC

Recruiting

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE)

Endometrial Cancer

United States
InventisBio Co., Ltd
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Solid Tumors

NSCLC | Solid Tumor, Adult | CRC

United States, Taiwan, Australia, Korea, Republic of
OncoC4, Inc.
National Cancer Institute (NCI)

Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)

Cervical Cancer | Small Cell Lung Cancer | Adenoid Cystic Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Melanoma | Pancreas Cancer | Metastatic... and other conditions

United States, Australia
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States

Search clinical trials for: MK3475-B84

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations